Loading…
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-189M | $-168M | $-144M | -32.1% | - | 25.4% |
| 2024 | $0M | $-157M | $-134M | $-110M | -29.1% | - | 33.6% |
| 2023 | $0M | $-113M | $-100M | $-98M | -31.4% | - | 48.1% |
| 2022 | $0M | $-71M | $-68M | $-58M | -19.5% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 0 | 0 | 0 | 0 |
| Operating Revenue | - | 0 | 0 | 0 | 0 |
| Operating Expense | - | 71.66 | 114.36 | 158.83 | 191.41 |
| Research And Development | - | 54.03 | 90.90 | 126.97 | 151.39 |
| Selling General And Administration | - | 17.63 | 23.45 | 31.87 | 40.02 |
| Total Expenses | - | 71.66 | 114.36 | 158.83 | 191.41 |
| Operating Income | - | -71.66 | -114.36 | -158.83 | -191.41 |
| Total Operating Income As Reported | - | -71.66 | -114.36 | -158.83 | -191.41 |
| EBITDA | - | -71.12 | -112.62 | -156.54 | -189.14 |
| Normalized EBITDA | - | -71.12 | -112.62 | -156.54 | -189.14 |
| EBIT | - | -71.66 | -114.36 | -158.83 | -191.41 |
| Interest Income | - | 4.02 | 14.19 | 25.02 | 23.61 |
| Net Interest Income | - | 4.02 | 14.19 | 25.02 | 23.61 |
| Interest Income Non Operating | - | 4.02 | 14.19 | 25.02 | 23.61 |
| Net Non Operating Interest Income Expense | - | 4.02 | 14.19 | 25.02 | 23.61 |
| Pretax Income | - | -67.64 | -100.16 | -133.81 | -167.80 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -67.64 | -100.16 | -133.81 | -167.80 |
| Net Income From Continuing And Discontinued Operation | - | -67.64 | -100.16 | -133.81 | -167.80 |
| Net Income From Continuing Operation Net Minority Interest | - | -67.64 | -100.16 | -133.81 | -167.80 |
| Net Income | - | -67.64 | -100.16 | -133.81 | -167.80 |
| Net Income Common Stockholders | - | -67.64 | -100.16 | -133.81 | -167.80 |
| Net Income Including Noncontrolling Interests | - | -67.64 | -100.16 | -133.81 | -167.80 |
| Normalized Income | - | -67.64 | -100.16 | -133.81 | -167.80 |
| Diluted NI Availto Com Stockholders | - | -67.64 | -100.16 | -133.81 | -167.80 |
| Basic Average Shares | 37.53 | 63.23 | 63.72 | 94.72 | - |
| Diluted Average Shares | 37.53 | 63.23 | 63.72 | 94.72 | - |
| Reconciled Depreciation | - | 0.54 | 1.73 | 2.29 | 2.27 |
| General And Administrative Expense | - | 17.63 | 23.45 | 31.87 | 40.02 |
| Other Gand A | - | 17.63 | 23.45 | 31.87 | 40.02 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Edgewise Therapeutics, Inc.this co. | EWTX | $4.0B | -23.87 | 7.67 | -32.1% | -20.88 |
| Celcuity Inc. | CELC | $4.5B | -25.47 | 44.85 | -176.1% | -29.21 |
| Travere Therapeutics, Inc. | TVTX | $4.3B | -168.11 | 37.40 | -22.2% | 203.89 |
| 10x Genomics, Inc. | TXG | $4.3B | -97.67 | 5.34 | -5.5% | 988.34 |
| Erasca, Inc. | ERAS | $4.1B |
| - |
| - |
| - |
| - |
| -33.13 |
| 12.69 |
| -38.3% |
| -31.96 |
| LivaNova PLC | LIVN | $4.0B | -16.70 | 3.37 | -20.2% | -34.40 |
| Oruka Therapeutics, Inc. | ORKA | $3.8B | - | 9.90 | -22.5% | - |
| Crinetics Pharmaceuticals, Inc. | CRNX | $3.7B | -7.85 | 3.68 | -46.9% | -7.02 |
| iRhythm Holdings, Inc. | IRTC | $3.5B | -79.19 | 23.10 | -29.2% | -1014.62 |
| Peer Median | - | -33.13 | 11.30 | -25.8% | -29.21 | |